Summit Therapeutics shares plunge following FDA rejection
SMMT Summit Therapeutics Inc
$10.67 -9.73%
View chart & analysis → - 1Summit Therapeutics shares fell more than 20% in pre-market trading.
- 2The U.S. Food and Drug Administration issued a CRL regarding Summit Therapeutics' drug approval application.
- 3Approval was denied despite confirming a 24% reduction in the risk of death for ivonescimab.
So what's the key point?
Summit Therapeutics shares fell by more than 20% during pre-market trading.
Source The Motley Fool · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.